

Nanoparticles of Esterified Polymalic Acid for Controlled Anticancer Drug Release

Alberto Lanz-Landázuri,¹ José Portilla-Arias,² Antxon Martínez de Ilarduya,¹ Montserrat García-Alvarez,¹ Eggehard Holler,² Julia Ljubimova,² Sebastián Muñoz-Guerra^{1*}

¹Departament d'Enginyeria Química, Universitat Politècnica de Catalunya, ETSEIB, Diagonal 647, 08028, Barcelona Spain.

²Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd. AHSP-A8220, Los Angeles, CA 90048, USA.




Figure S1. ¹H NMR spectrum of PMLA-Et₁₀₀.




Figure S2. ¹H NMR spectrum of PMLA-Bu₁₀₀.




Figure S3. ¹H NMR spectrum of *coPMLA-Et*₅₀*H*₅₀. (*) DMSO and water solvent peaks.




Figure S4. ¹H NMR spectrum of *coPMLA-Bu*₅₀*H*₅₀. (*) DMSO and water solvent peaks.




Figure S5. Deconvoluted GPC chromatograms of *coPMLA-Et*₅₀*H*₅₀ and *coPMLA-Bu*₅₀*H*₅₀ after incubation in aqueous buffer at pH 7.4 and 5.0 for the indicated times.




Figure S6. ¹H NMR spectra of the degradation products of PMLA-Bu₁₀₀ incubated at pH 7.4 and 37 °C. (*) impurity.




Figure S7. ^1H NMR spectra of the degradation products of $coPMLA-Bu_{50}H_{50}$ incubated at pH 7.4 and 37°C .




Figure S8. Particle size distributions profiles measured by light scattering.